|Bid||4.9100 x 3200|
|Ask||4.9200 x 1400|
|Day's Range||4.7500 - 4.9250|
|52 Week Range||2.9300 - 17.3700|
|Beta (5Y Monthly)||2.36|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 05, 2020 - Nov 09, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||12.63|
Clovis (CLVS) reports dismal second-quarter 2020 results. Sales of the company's sole marketed drug, Rubraca, decline sequentially. Shares down.
Clovis (CLVS) delivered earnings and revenue surprises of -8.82% and -10.67%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Clovis Oncology Announces Second Quarter 2020 Operating Results